Akorn receives FDA approval for Ephedrine Sulfate Injection
LAKE FOREST - Generics pharmaceutical company Akorn has received approval from the U.S. Food and Drug Administration for its New Drug Application for Ephedrine Sulfate Injection.
Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The FDA's approval is for the drug's USP 50 mg/mL in 1 mL single dose ampule.
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked.
If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.